title: Effects of chronic treprostinil treatment on experimental right heart hypertrophy and failure.
abstract: BACKGROUND
  Right heart function is an important predictor of morbidity and mortality in pulmonary arterial hypertension and many CHD. We investigated whether treatment with the prostacyclin analogue treprostinil could prevent pressure overload-induced right ventricular hypertrophy and failure.
  
  
  METHODS
  Male Wistar rats were randomised to severe pulmonary trunk banding with a 0.5-mm banding clip (n=41), moderate pulmonary trunk banding with a 0.6-mm banding clip (n=36), or sham procedure (n=10). The banded rats were randomised to 6 weeks of treatment with a moderate dose of treprostinil (300 ng/kg/minute), a high dose of treprostinil (900 ng/kg/minute), or vehicle.
  
  
  RESULTS
  Pulmonary trunk banding effectively induced hypertrophy, dilatation, and decreased right ventricular function. The severely banded animals presented with decompensated heart failure with extracardial manifestations. Treatment with treprostinil neither reduced right ventricular hypertrophy nor improved right ventricular function.
  
  
  CONCLUSIONS
  In the pulmonary trunk banding model of pressure overload-induced right ventricular hypertrophy and failure, moderate- and high-dose treatment with treprostinil did not improve right ventricular function neither in compensated nor in decompensated right heart failure.
authors.affiliation: 1Department of Cardiology,Institute of Clinical Medicine,Aarhus University Hospital,Aarhus,Denmark.
authors.forename: Sofie
authors.initials: S
authors.lastname: Axelgaard
authors.affiliation: 1Department of Cardiology,Institute of Clinical Medicine,Aarhus University Hospital,Aarhus,Denmark.
authors.forename: Sarah
authors.initials: S
authors.lastname: Holmboe
authors.affiliation: 2The MR Centre,Institute of Clinical Medicine,Aarhus University Hospital,Aarhus,Denmark.
authors.forename: Steffen
authors.initials: S
authors.lastname: Ringgaard
authors.affiliation: 1Department of Cardiology,Institute of Clinical Medicine,Aarhus University Hospital,Aarhus,Denmark.
authors.forename: Thomas K
authors.initials: TK
authors.lastname: Hillgaard
authors.affiliation: 1Department of Cardiology,Institute of Clinical Medicine,Aarhus University Hospital,Aarhus,Denmark.
authors.forename: Stine
authors.initials: S
authors.lastname: Andersen
authors.affiliation: 1Department of Cardiology,Institute of Clinical Medicine,Aarhus University Hospital,Aarhus,Denmark.
authors.forename: Mona S
authors.initials: MS
authors.lastname: Hansen
authors.affiliation: 1Department of Cardiology,Institute of Clinical Medicine,Aarhus University Hospital,Aarhus,Denmark.
authors.forename: Asger
authors.initials: A
authors.lastname: Andersen
authors.affiliation: 1Department of Cardiology,Institute of Clinical Medicine,Aarhus University Hospital,Aarhus,Denmark.
authors.forename: Jens E
authors.initials: JE
authors.lastname: Nielsen-Kudsk
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D017380:Hypertrophy, Right Ventricular / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D055104:Infusions, Subcutaneous; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D016278:Ventricular Function, Right / Q000187:drug effects*
chemical_list: D000959:Antihypertensive Agents; D011464:Epoprostenol; C427248:treprostinil
keywords: Right ventricular dysfunction; prostacyclin; pulmonary hypertension